Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment

Air Force Military Medical University of People's Liberation Army

Status: Not yet enrolling

Conditions: Bladder Cancer; Kidney Cancer; Prostate Cancer

Treatments: Other: No Interventions

Study type: Observational

Funder types: Other

Identifiers

NCT06762925

KY20242214

Details and patient eligibility

About

This study aims to validate the accuracy and clinical value of METTL3 as a biomarker for predicting immune therapy response in patients with urinary tract tumors through observational studies.

Enrollment: 450 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients diagnosed with urinary system tumors through pathological examination;
2. Meet specific clinical stages and surgical treatment standards;
3. Intraoperative tissue resection meets the sample testing standards;
4. The patient is willing to participate in the study and sign an informed consent form.

Exclusion criteria

1. Not meeting the specific clinical stage and not receiving surgical treatment;
2. Abnormal mental behavior;
3. Intellectual disability;
4. Age under 18 years old or over 75 years old;
5. Low understanding and communication skills.

Trial design

450 participants in 3 patient groups

Bladder Cancer

Treatment:

Other: No Interventions

Prostate Cancer

Treatment:

Other: No Interventions

Kidney Cancer

Treatment:

Other: No Interventions